
    
      This is a randomized, double-blind, placebo-controlled study to assess the safety,
      tolerability, pharmacokinetics, and pharmacodynamics of KA34 when administered via
      intra-articular injection to subjects with osteoarthritis of the knee. OA patients are
      randomized to receive either placebo or KA34 active drug in the range of 50-400 ug by
      intra-articular injection. The first portion of the study is with single ascending doses, the
      second portion of the study is with multiple ascending doses.
    
  